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Abstract
Obstructive sleep apnea (OSA) is a common sleep disorder characterized by complete 
cessation of upper airflow during sleep, leading to repetitive episodes of desaturations 
and arousals. The symptoms include excessive daytime somnolence and are associated 
with a significant cardiovascular morbidity and mortality. The prevalence of OSA is 
higher in men with an approximate rate of 14 and 5% in women respectively. Typical 
risk factors for obstructive sleep apnea in the normal adult population are obesity, aging, 
gender, menopause, ethnicity, genetical predisposition, craniofacial anatomy, smoking, 
alcohol consumption and some other factors such as REM sleep, surface tension, and 
impaired sensory processing. Several screening questionnaires can be performed in out-
patient settings to identify the patient symptoms. Polysomnography is considered as the 
gold standard for diagnosis of OSA. Different surgical treatments and devices are readily 
available for an effective management of this disease. Proper diagnosis and treatment 
improves not only the quality of life but also relatively decreases patient morbidity and 
mortality. A multifaceted approach is necessary for an accurate management of the OSA.
Keywords: obstructive sleep apnea, excessive daytime somnolence, obesity, 
polysomnography, quality of life
1. Introduction
The first clear modern description of obstructive sleep apnea (OSA) was given by Burwell in 
1956 in the publication entitled, “Extreme Obesity Associated with Alveolar Hypoventilation: 
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A Pickwickian Syndrome.” The name came from Charles Dickens’ The Posthumous Papers 
of the Pickwick Club (1837). It is unclear if the patient named Joe with overweight exhibited 
symptoms of OSA, and it took another decade before Gastaut and colleagues in 1966 recog-
nized OSA in obese patients and noted these nocturnal disturbances to possibly be linked to 
their daytime somnolence [1].
Obstructive sleep apnea (OSA) is a potentially serious and life-threatening disorder affecting 
millions of people around the world. It is a sleep-related respiratory condition, characterized 
by the complete or partial collapse of breathing because of a narrowing or closure of the upper 
airway during sleep, resulting in intermittent cessations of breathing (apneas) or reductions in 
airflow (hypopneas) despite ongoing respiratory effort [2]. The symptoms include excessive 
daytime sleepiness, Mood changes, Fragmented sleep, as well as the decreased health-related 
quality of life. Patients often complain of snoring, Gasping or choking, frequent nocturnal awak-
enings, early morning headaches, poor concentration and coordination, anxiety, irritability, and 
insomnia, yet many patients are unaware of these symptoms and disease onset is insidious [3, 4]. 
The underlying mechanism of OSA is still under investigation, but it is precisely multifaceted.
The economic burden of OSA is substantial due to its high prevalence and economic costs in 
the community globally, the profound clinical effects on an individual’s cognitive and general 
functioning and the increased risk of adverse health complications [2]. Moreover, mount-
ing evidence suggests that OSA can increase the risk of cardiovascular diseases (hyperten-
sion, coronary heart failure, stroke etc.), metabolic syndrome, Neurological problems and 
increased in societal effects such as traffic accidents [3, 5–7].
2. Prevalence of OSA
OSA is a common chronic disorder with an estimated prevalence of 2–4% in general and 
the disorder was believed to be rising continuously with an approximate rate of 14% in men 
and 5% in women aged 30–70 years respectively [8–10]. It is higher in patients with obesity; 
diabetes mellitus type II and other cardiovascular disorders which includes ischemic heart 
disease, heart failure, cardiac arrhythmias, stroke, atherosclerosis and myocardial infarction 
[8, 10]. Research on current prevalence (Seventh Joint National Committee) shows that OSA 
was identified as a secondary cause of Hypertension (HTN) and ranges from 37 to 56%, the 
prevalence rate of OSA in resistant hypertensive patients were estimated to be 70–83% [11]. 
Among the pediatric population, the rate affects between 1.2 and 5.7% and it is estimated that 
36% of obese children are at high risk of OSA [12]. Since it is reported that more than 85% of 
patients with OSA symptoms have never been diagnosed clinically [13].
3. Pathophysiology of OSA
The pathogenesis of OSA can be multifactorial, complex and incompletely understood 
[13, 14]. The changes in upper airway anatomy tissue characteristics and neuromuscular 
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function, sleep-dependent changes can assume to play the major role between the individuals 
(Figure 1). Certain factors that may contribute to OSA include obesity, thickened lateral pha-
ryngeal walls, nasal congestion, enlarged uvula, facial malformations, and tonsillar hypertro-
phy. As the patient falls asleep, the muscle tone of the nasopharynx is reduced during sleep 
and airways become contracted. These episodes are typically accompanied by repeated oxy-
hemoglobin desaturation, oxygen levels in the body start to drop and carbon dioxide levels 
rise by short micro-arousals by the patient when the airway patency is restored. This causes 
activation in sympathetic nervous system and contraction of nasopharyngeal tissue, which 
results in obstruction of the airway. These cyclic episodes continue throughout the night 
with reduced deep Non-Rapid eye movement sleep (NREM) and Rapid eye movement sleep 
(REM) [13]. Several studies have confirmed that the airway dilating muscles in OSA patients 
can no longer resist the negative pressure in airways during inspiration. In severe cases, the 
respiratory events can occur 50–100 times per hour; each event lasts for about 20–40 s [9].The 
severity of OSA is measured by the apnea-hypopnea index (AHI). The frequency of apneas 
and hypopneas per hour of sleep. Apnea is defined by complete obstruction of the upper air-
ways lasting for at least 10 s (i.e. airflow restriction by more than 90% (according to AASM cri-
teria). Hypopnea is defined as airflow restriction more than 30% (according to AASM criteria) 
Figure 1. Pathophysiology of OSA.
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lasting for more than 10s. The oxygen desaturation index (ODI) is defined as the number of 
desaturations per 1 h of monitored sleep when oxygen saturation is reduced as compared to 
the baseline standard level. The respiratory effort related arousal (RERA) can also be used. 
RERA is defined as an episode characterized by an increased respiratory effort caused by 
upper airway airflow reduction resolved with arousal and accompanied in most cases with 
hypoxemia. The respiratory disturbance index (RDI) is the sum of RERA and AHI [9, 15].
According to the third edition of the International Classification of Sleep Disorders (ICSD-3), 
obstructive sleep apnea (OSA) is defined as polysomnography derived obstructive respiratory 
disturbance index (RDI) ≥5 events/h associated with typical OSA symptoms, or an obstructive RDI 
≥15/h in the absence of clinical OSA symptoms [9]. According to American Academy of sleep medi-
cine (AASM), OSA is commonly divided into three levels of severity as detailed in Table 1 below.
4. Diagnosis of OSA
The diagnosis of Obstructive sleep apnea starts with thorough history and physical exami-
nation to elucidate the signs and symptoms of the syndrome. Common symptoms patients 
complain of snoring, disturbed sleep, daytime somnolence, decreased libido as well as a his-
tory of hypertension, cardiovascular disease, and diabetes. Depending on the nonspecific and 
other variable features of OSA, its diagnosis based on a clinician’s subjective analysis alone 
may be inaccurate [13]. A number of out-patient screening questionnaires such as Epworth 
sleepiness scale (ESS), Berlin Questionnaire STOP-BANG questionnaire, Sleep Apnea of Sleep 
Disorder Questionnaire SA-SDQ, OSA50 questionnaire etc. to help and identify patients with 
OSA [9, 16, 17]. Advances in sleep medicine and the availability of improved diagnostic tools 
have led to a better recognition and treatment of the disease. The outpatient examination 
should be repeated and the patients should be then referred, depending on the result of the 
follow-up examination, to a sleep laboratory [8].
An overnight polysomnography is considered to be the gold standard for the diagnosis of 
obstructive sleep apnea (Figures 1 and 2). A screening tool is necessary to stratify patients 
based on their clinical symptoms, their physical examinations, and their risk factors, in order 
to ascertain patients at high risk and in urgent need of PSG and/or further treatment [18]. The 
diagnostic PSG was performed using the computerized polysomnographic system including 
the monitoring of electroencephalogram (EEG), submental and anterior tibial electromyo-
gram (EMG), oxygen saturation (SaO
2
), electrocardiogram (ECG), inductance plethysmography 
OSA severity RDI measurement (events/hr)
Mild OSA ≥ 5
Moderate OSA ≥ 15
Severe OSA ≥ 30
Table 1. OSA severity is defined by the AASM.
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Figure 2. Polysomnography representation of airflow obstruction.
Figure 3. Polysomnography representation of airflow obstruction with desaturation.
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of chest walls and abdomen, nasal pressure sensor, and oronasal thermistor. The polysom-
nographic recording was scored manually by the sleep specialist. The sleep stage scoring 
and event scoring were done in accordance with the American Academy of Sleep Medicine 
(AASM) Manual for the Scoring of Sleep and Associated Events [19] (Figure 3).
Total obstructive Apnea/hypopnea index (AHI) was calculated as the number of obstructive 
apneas and hypopneas per hour of total sleep time (TST). The threshold for diagnosis of OSA 
was set at an AHI ≥5 and the severity of OSA was arbitrarily defined by cut-off levels of AHI 
[20]. Additional diagnostic models for OSA include portable sleep monitors, radiographic stud-
ies for anatomic analysis. It is necessary to remember that OSA can occur and progress over 
short periods of time, and its association with significant morbidity, coupled with the relatively 
low risk and high reward of therapy, that requires a thorough workup and treatment plan [13].
5. Complications of OSA
Several risk factors have been identified in the development of OSA namely male gender(up to 
age 65), increasing age, menopause, overweight, truncal obesity reflected by several markers 
including BMI, neck circumference, and waist-to-hip ratio, craniofacial abnormalities, upper 
airway anatomy, smoking, alcohol, and genetic predisposition [21]. Obesity is considered as 
the most important clinical risk factor for the development of OSA. Several studies have shown 
that more than half of the prevalence of OSA is attributable to excess body weight as opposed 
to substantial improvement with weight reduction [19]. Fat Deposition around the pharyn-
geal airway and abdomen may likely to reduce residual capacity function, which would be 
predicted to reduce lung volume tethering effects on the upper airway [22]. This latter mecha-
nism emphasizes the great importance of central obesity as compared with peripheral obesity 
since it is the abdomen much more than the thighs that affect upper-airway size. Therefore, 
obesity has been associated with functional impairment in upper airway muscles [23]. 
Figure 4 represents the complications of OSA.
The prevalence of OSA increases with age and the gender differences diminish significantly 
after menopause [21]. Although several potential mechanisms have been proposed, the expla-
nation for this aging increase in the prevalence of OSA remains unknown. The exact mecha-
nism of OSA was not fully known but, it begins as just loud snoring, then gradually over a 
period of time cessations of breathing and symptoms of excessive sleepiness develop, and 
thereafter may remain stable or worsen with weight gain. Numerous studies have attempted 
to know the cause of the age-related impact on OSA, no definitive conclusions have been 
reached [22]. Anatomical and pathophysiological susceptibility to OSA appears to increase 
with age in older people, who had a poorer responsiveness of pharyngeal dilator muscles, the 
genioglossus negative pressure stimuli appear to deteriorate with aging [23].
Craniofacial anatomy is probably one of the important factors in non-obese cases with 
OSA. Several soft and hard tissue factors may alter the mechanical properties of the upper 
airway muscles and increase its propensity to collapse during sleep. Features such as retrog-
nathia, tonsillar hypertrophy, soft palate, inferiorly positioned hyoid bone, maxillary and 
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mandibular retroposition, can narrow upper airway dimensions and promote the occurrence 
of apneas and hypopneas during sleep. Differences in craniofacial structures may alter the risk 
for obstructive sleep apnea across different racial groups. Therefore, different racial groups 
are prone to develop obstructive sleep apnea at varying degrees of obesity, clinicians should 
consider the possibility of this disorder particularly in the presence of clinically detectable 
craniofacial abnormalities [4]. According to clinic-based studies, the significant gender gap in 
the prevalence of OSA was reported. Recent population-based studies have confirmed that the 
prevalence of OSA is higher in men than women. This difference between clinic and epide-
miological prevalence suggests several explanations for the gender gap. Firstly, women may 
not present with a similar symptomatic profile as men (loud snoring, nocturnal snorting or 
gasping, and witnessed apneas). Women were more likely to present with atypical complaints 
namely insomnia, depression, fatigue, and lack of energy, less likely to have apnea. The other 
reasons for this gender disparity are differences in body fat distribution (or other gender-
related upper airway anatomy differences), control of ventilation, physiology of the pharyn-
geal airway dilator muscles activation, and hormonal differences. Therefore, the evidence 
suggests that women are underdiagnosed and untreated for OSA compared to men [21].
Social factors such as smoking and alcohol consumption are considered as possible risk fac-
tors for progression of obstructive symptoms [13]. Epidemiological studies show that current 
smoking is associated with high prevalence of snoring and obstructive sleep apnea. Smoking 
can alter the upper airway properties and increase its collapsibility during sleep [4]. Ingestion 
of alcohol especially at dinner or during the evening relaxes dilator muscles, increases upper 
airway resistance, and decreases respiratory reflexes, and so it leads to snoring and apnea 
episodes in susceptible individuals [24].
Figure 4. Complications of OSA.
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Familial aggregation of obstructive sleep apnea was first recognized in the 1970s by Strohl 
and co-workers in a family with several affected individuals. The relative risk of obstruc-
tive sleep apnea can be two-four fold higher in first-degree relatives [23]. Genetic factors of 
obesity, soft tissue characteristics, and craniofacial abnormalities together given the wealth of 
evidence implicating these factors in the pathogenesis of the disorder. However, the genetic 
basis of obstructive sleep apnea needs a better attention, the available study reports suggest 
that inquires about family history can help the clinician to diagnose the disorder early for fur-
ther treatment [4].Medications such as muscle relaxants, sedative hypnotics (benzodiazepines 
and barbiturates), narcotics, opioid analgesics and other central nervous system depressants, 
preferentially inhibit upper airway muscle activity while also depressing the respiratory cen-
ters of the brain [24].
There are several other risk factors associated with OSA namely nasal congestion, pregnancy, 
menopause, hypothyroidism, diabetes and pregnancy. Available data suggest that OSA is 
three times higher in patients with insulin resistance than it is in the general population. 
Hypothyroidism leads to deposition of mucoproteins in the upper airway that causes enlarge-
ment of the soft palate, pharyngeal and laryngeal mucous membranes, thereby increasing 
the propensity for upper airway collapse during sleep. Thus, patients with hypothyroidism 
may have increased susceptibility to obstructive sleep apnea. Pregnant women also experi-
ence higher rates of snoring particularly in the third trimester due to some of the physiologic 
changes that accompany pregnancy (e.g., higher progesterone levels, decrease in sleep time in 
the supine position). Thus, early case identification may have implications for maternal and 
fetal outcomes. Knowledge of risk factors for obstructive sleep apnea is therefore crucial for 
proper diagnosis and treatment at those with the highest risk [4, 21].
6. Pharmacotherapy of OSA
OSA is a common condition in which nasal and oral airway ceases in spite of continued 
diaphragmatic efforts and is associated with poor quality of life, increased healthcare-
related costs. Numerous efficacious treatments are available, but the patient should not shy 
away from therapeutic options, and medical practitioners should not hesitate to implement 
treatment regimens in addressing the problem of OSA. Treatment of OSA depends on the 
severity, duration, and cause of the patient’s symptoms as well as the patient’s lifestyle, 
comorbidities, and overall health [13]. The detailed treatment procedures are discussed 
below (Figure 5):
6.1. Positive airway pressure treatment (PAP)
First-line therapy for most patients with OSA continues the use of PAP especially in patients 
with greater apnea-hypopnea index score (AHI). PAP devices work as pneumatic support 
that allows maintaining adequate airway patency above a critical value (pressure value 
below which the airway collapses). The device is applied to the patient, through a nasal 
or oronasal mask during sleep in overnight at a required positive pressure. The pressure 
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can be varying with the severity of OSA and high pressures are required to avoid apneas 
during rapid eye movement sleep (REM) in the supine position or in severe obesity cases. 
However, patient compliance for PAP devices levels average 40–50% due to mask leaks, 
nasal congestion and sleep disruption. In moderate to severe OSA cases PAP therapy is 
remains as life-long treatment, many advanced PAP ventilators such as continuous posi-
tive airway pressure (CPAP), auto-titrating positive airway pressure (APAP), and bi-level 
positive airway pressure (BPAP) therapies have been commercialized in order to maintain 
efficacy and maximal comfort for patients [8, 25].
6.2. Continuous positive airway pressure (CPAP)
CPAP therapy was initially applied as treatment of OSA by Sullivan and colleagues in 1981 
[26]. Since its initial description, the device is considered as the gold standard treatment for 
OSA. The clinical application of this CPAP has deeply modified the course of the disease 
over the last three decades, offering to thousands of patients the first non-invasive method 
to control their disorder. Worldwide, CPAP is constantly recommended as the first-choice 
treatment for patients with moderate to severe OSA. Continuous PAP (CPAP), generally 
administered through the nose (nCPAP), delivers a single pressure to the posterior pharynx 
throughout the night and acts as a pneumatic splint that maintains the patency of the upper 
airway in a dose-dependent fashion. The best pressure for CPAP treatment is typically 
determined during an in-laboratory attended sleep study. CPAP therapy is indicated in all 
patients with an AHI greater than 15, independently from the presence of comorbidities, 
type of work and severity of symptoms; if the AHI is above 5 and below 15, CPAP is indi-
cated in the presence of symptoms (i.e. sleepiness, impaired cognition, mood disorders) 
or in the presence of hypertension, coronary artery disease or previous cerebrovascular 
accidents [8, 25, 27].
Figure 5. Pharmacotherapy of OSA.
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6.3. Oral appliances
Over the last 10 years, oral appliances have gained increasing recognition as a useful alterna-
tive to CPAP for the treatment of patients with mild to moderate OSA and for those who do 
not tolerate or adhere to CPAP. The most frequently used oral appliances are mandibular 
advanced splints (MAS). These splints attach to both the upper and lower dental arches in 
order to advance and retain the mandible in a forward position, further the size of upper 
airway will be widened particularly in its lateral dimension, and the function of upper airway 
dilator muscles, particularly the genioglossus, will improve through the protrusion of the jaw 
during sleep [30]. As the pharyngeal collapsibility is reduced, the risk of apnoeic events will 
be lowered. Side effects that are more persistent include arthralgia, teeth pain and occlusal 
changes [8]. Several randomized trials have evaluated the efficacy of MAS versus CPAP in 
mild to moderate obstructive sleep apnea, treatment with MAS significantly reduces the num-
ber of apneas/hypopneas (normalizing nocturnal SaO2), reduces daytime somnolence, and 
improves quality of life [28]. It has been demonstrated that the treatment success is achieved 
in patients with the following characteristics: young people, women, patients with small 
necks, and milder OSA [29]. Another group of oral appliances includes the orthodontic micro-
implants that are connected to the extra-orally anchored mask. Overnight application of these 
devices significantly reduces the AHI and few studies have shown similar efficacy compared 
with MAS. This type of implants could be used in patients with few teeth, exaggerated gag 
reflex, or intolerance for classic MADs [27]. Although its efficacy is still undetermined to rec-
ommend the use of these oral appliances in clinical practice [30].
The role of surgery in the management of OSA has been widely explored in an attempt to find 
a treatment option that could be definitive [6]. A wide variety of procedures are available, 
many of which are directed at the site of obstruction [2]. Initially, Kuhlo and colleagues in 
1969 followed by Lugaresi and colleagues in 1970 were the first to treat OSA effectively (or 
Pickwickian syndrome) by means of a tracheostomy. By bypassing the upper airway, trache-
ostomy is purported to be curative for OSA. The surgical procedure is effective at preventing 
OSA-related arrhythmias, reducing pulmonary artery pressures, and improving hyperten-
sion and diabetes in patients with OSA. Unfortunately, tracheostomy has several problems 
including patient dissatisfaction (e.g., psychosocial aspects), perioperative complications 
(e.g., wound infection, tissue necrosis, bleeding), recurrent bronchitis, granulation tissue, 
trachea-innominate fistula formation, and stoma stenosis [31].
6.4. Surgical treatment
The aim of the surgery is to remove the cause of upper airway obstruction and to widen 
the airway, after a precise detection of the site where the obstruction occurs [8]. The most 
common sites of obstruction are the oropharyngeal tract (collapse of the retropalatal and 
retrolingual regions due to macroglossia, low-lying soft palate or enlarged tonsils) and the 
nose (congestion, polyposis, chronic rhinitis) [32]. Tonsillectomy and adenoidectomy are 
the most commonly used surgical procedures to treat OSA in children and are highly effec-
tive [8]. Uvulopalatopharyngoplasty (UPPP), either conventional or laser assisted (LAPP), 
is a widely used surgical procedure for the treatment of OSA. This technique consists of the 
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resection of the uvula, part of the soft palate and tissue excess in the oropharynx, and is 
usually performed with simultaneous tonsillectomy [31]. The success rate for UPPP alone is 
30, 60% along with a tonsillectomy. The common side effects of UPPP surgery include velo-
pharyngeal insufficiency (up to one-third of patients), dry throat and swallowing difficulty 
[33]. Tracheotomy is the most established surgical treatment for OSA and must be carried out 
in selected patients with severe OSA for whom all other treatment approaches have failed 
[34]. Maxillomandibular advancement (MMA) is indeed a highly effective treatment for tra-
cheotomy. In fact, the efficacy of most treatments decreases with age and weight gain. This 
indicates a major factor determining the recurrence of OSA after surgery [8].
6.5. Weight control and bariatric surgery
Excess body weight and obesity are considered as largest predisposing factors for obstructive 
sleep apnea (OSA) over 70% of OSA patients have obesity. Population-based studies have 
documented a strong correlation between body mass index (BMI) and apnea-hypopnea index 
(AHI). Observational studies on the effects of dietary or surgical weight loss which show that 
reducing obstructive sleep apnea severity is possible with a decrease in body weight where a 
significant reduction in AHI score can be seen [4]. In patients with morbid obesity (BMI > 40) 
bariatric surgery, including gastric bypass and bandage, is presented as the optimal alterna-
tive for achieving considerable weight reduction when conservative treatments like CPAP, 
oral devices, and upper airway surgeries are failed [35]. Evidence has demonstrated, that 
bariatric surgery is co-adjuvant in the treatment of OSA, effectively reducing severity in up to 
75% of cases. But, the remission rate for OSA 2 years after bariatric surgery in relation to the 
quantity of weight loss is up to 40% [27].
6.6. Educational and behavioral therapies
Educational and behavioral therapies are the first step in approaching patients with OSA, 
independently from the treatment chosen. Patients should be instructed to avoid risk fac-
tors such as tobacco, alcohol consumption (particularly in the evening), using sedatives and 
hypnotics. The physician main priority is to explain the patients the role that obesity plays 
in their disorder, and advice to maintain an optimal weight [8]. Another goal of the edu-
cational therapy is to help each patient to recognize the need for regular use of nocturnal 
CPAP. Recent reports suggest that a supportive intervention can significantly increase com-
pliance in patients with moderate to severe OSA [36].
6.7. Positional therapy
Body position during sleep greatly affects the number and severity of obstructive events due 
to anatomical and physiological mechanisms. The supine position, mainly due to effects of 
the gravity on the tongue and soft palate position, is generally associated with an increased 
number of apneas/hypopneas [37]. Postural OSA can take place mainly in patients sleep-
ing in the supine position. If postural OSA is diagnosed with standard criteria, patients 
can benefit from a positional therapy (PT). The therapy includes “Tennis ball technique” 
consisting of a tennis ball strapped to the back to discourage supine position, supine alarm 
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devices and a number of positional pillows. The success rate can be considered by proper 
selection of patients and post-treatment AHI has to below 10. However, trials on the long-
term effects of PT on important outcomes, such as metabolic and neurocognitive changes, 
are still need to be studied [38].
A number of novel therapeutic options for management of obstructive sleep apnea are 
now under evaluation. The stimulation of upper airway muscles has been considered as 
a potential approach to prevent obstructive apneas over the years [39]. The Inspire Upper 
Airway Stimulation is the first system recently approved in patients with moderate to 
severe OSA, who are intolerant to use CPAP. Trials conducted on patients with moderate 
to severe OSA intolerant to CPAP showed 68% reduction in the median AHI score with a 
subjective improvement in daytime sleepiness and quality of life over 12 months of period 
[40]. Other emerging treatment options are intended for patients with mild disease or as 
a remedy for simple snoring. Among these nasal expiratory PAP (nEPAP) has recently 
gained attention [41]. The nEPAP is a disposable adhesive device placed over each nos-
tril in order to increase the airflow resistance during the exhalation with a consequent 
improvement in the upper airway patency. A study in patients with mild to moderate 
OSA, nEPAP significantly reduce apneas, snoring, AHI score and improves subjective day-
time sleepiness [42]. Therefore, further research is necessary to assess the potential benefits 
of this evolving technology.
7. Conclusion
Over recent decades, diverse studies have carried out to improve our understanding of 
the physiological mechanisms and outcomes of OSA, providing relevant insights into its 
potential contribution to the development of various treatment alternatives. Although an 
effective treatment is still unavailable, the combination of several therapeutic strategies to 
prevent of risk factors, improving sleep disturbance and quality of life should be the focus 
in patients with OSA. A multidisciplinary approach is needed for a treatment protocol 
that is able to directly address the etiological processes of the disease in order to reduce 
its prevalence.
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